TAR-210's Potential to Improve Outcomes in Intermediate-Risk NMIBC

Roger Li, MD, genitourinary oncologist, Moffitt Cancer Center, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) with susceptible FGFR alterations.

The agent, an erdafitinib (Balversa) intravesical delivery system, is currently being studied in the phase 3 MoonRISe-1 trial (NCT06319820) vs intravesical chemotherapy in this patient population. Li presented findings from the study at the 2024 American Urological Association (AUA) Annual Meeting.

Transcription:

0:09 | For TAR -210 specifically, it makes a lot of sense to be tested in this intermediate-risk NMIBC cohort, because in this patient population, we know that there is an up to 80% incidence rate of FGFR3 alterations. And we are also using tissue samples as well as urine samples to do a very comprehensive, all-encompassing capture of these patients so that either they have the alterations on their prior tissues or within the urine that is detected at the start of study. I am very optimistic given the first-in-human study and also given what we know from the [a prior] study…that TAR-210 is going to show superior efficacy than intravascular chemotherapy.

1:03 | I think what the future holds really is for the platform of TAR itself. So as you know, there are a lot of SunRISe studies [with] 1 through 5 testing it in very various non-muscle invasive bladder cancer settings, and that is also using the TAR-200 device, which eludes out gemcitabine. I think there is no limitation on what type of small molecule that we can elude out from the stent. The TAR platform can actually elude up to 3 different drugs simultaneously, so we can potentially design trials using this device with simultaneous combination treatment based on the molecular characteristics of the tumor. And I think that is really the way of the future where we are able to bring precision medicine into bladder cancer by pairing up the molecular testing that we can do using the urine itself and also the tissue and tailor the therapy accordingly.